Lana Zhovtis Ryerson

Learn More
BACKGROUND Natalizumab (NTZ), a monoclonal antibody to human α4β1/β7 integrin, is an effective therapy for multiple sclerosis (MS), albeit associated with progressive multifocal leukoencephalopathy (PML). Clinicians have been extending the dose of infusions with a hypothesis of reducing PML risk. The aim of the study is to evaluate the clinical consequences(More)
We discuss the case of a patient with Progressive Multifocal Leukoencephalopathy (PML), developed after treatment with Natalizumab for 42 months for relapsing remitting multiple sclerosis (RRMS). Imaging was consistent with widespread PML with features that portended a high risk of development of Immune Reconstitution Inflammatory Syndrome (IRIS). After(More)
Adult-onset, chronic progressive spastic paraparesis may be due to a large number of causes and poses a diagnostic challenge. There are no recent evidence-based guidelines or comprehensive reviews to help guide diagnostic work-up. We survey the literature on chronic progressive spastic paraparesis, with special emphasis on myelopathies, and propose a(More)
BACKGROUND Dimethyl fumarate (DMF) was approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis (RRMS) based on two phase III randomized clinical trials (RCTs). There were not enough non-White patients enrolled in these RCTs to allow for subgroup analysis based on race. Efficacy and tolerability of DMF(More)
A 66-year-old man with hypertension presented with right-sided numbness and slurred speech. MRI revealed a large left frontoparietal area of T2-weighted hyperintensity with focus of central enhancement (figure , A and B). The patient's symptoms self-resolved within weeks. Over the next 2 years, he experienced multiple relapses including encephalopathy(More)
  • 1